Listen
EMCITATE (tiratricol) - Peripheral thyrotoxicosis
Opinions on drugs -
Posted on
Sep 25 2025
Reason for request
Inclusion on list
Summary of opinion
Unfavourable opinion for reimbursement in “the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-DudleySyndrome), from birth”.
Clinical Benefit
| Insufficient |
The clinical benefit of EMCITATE (tiratricol) dispersible tablets is insufficient in the MA indication to justify public funding. |
Clinical Added Value
| Not applicable |
Documents
English version
Contact Us
Évaluation des médicaments
